SIIC MEDTECH<08018> - Results Announcement SIIC Medical Science and Technology (Group) Limited announced on 09/05/2003: (stock code: 08018 ) Year end date: 31/12/2003 Currency: HKD Auditors' Report: N/A Review of Interim Report by: Audit Committee Important Note: This result announcement form only contain extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be view on the GEM website at http://www.hkgem.com (Unaudited ) (Unaudited ) Last Current Corresponding Period Period from 01/01/2003 from 01/01/2002 to 31/03/2003 to 31/03/2002 Note ('000 ) ('000 ) Turnover 2 : 325,740 237,420 Profit/(Loss) from Operations : 53,316 46,428 Finance cost : (70) 0 Share of Profit/(Loss) of Associates : 3,337 3,795 Share of Profit/(Loss) of Jointly Controlled Entities : (286) (352) Profit/(Loss) after Tax & MI : 21,067 18,864 % Change over Last Period : +11.7 % EPS/(LPS)-Basic (in dollars) 3 : 0.034 0.03 -Diluted (in dollars) 3 : N/A N/A Extraordinary (ETD) Gain/(Loss) : 0 0 Profit/(Loss) after ETD Items : 21,067 18,864 1st Quarterly Dividend : N/A N/A per Share (Specify if with other : N/A N/A options) B/C Dates for 1st Quarterly Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A For and on behalf of SIIC Medical Science and Technology (Group) Limited Name : Wong Mei Ling, Marina Title : Company Secretary Responsibility statement The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information. Remarks: 1. Basis of preparation The principal accounting policies adopted in preparing the unaudited consolidated results of the Group conform with accounting principles generally accepted in Hong Kong and accounting standards issued by the Hong Kong Society of Accountants. The consolidated income statement have been prepared under the historical cost convention as modified for revaluation of certain properties. 2. Turnover Turnover represents the net amounts received and receivable for goods sold by the Group to outside customers during the period. For the period ended 31st March, 2003 and 2002, the Group was engaged in the manufacture and sale of Chinese medicine and health supplement products. More than 90% of the Group's turnover, contribution to operating profit and assets was attributable to this business segment and located in the PRC. 3. Earnings per share The calculation of the basic earnings per share for the period is based on the following data: For the three months ended 31st March 2003 2002 Earnings: Net Profit for the period and earnings for the purpose of basic earnings per share HK$21,067,000 HK$18,864,000 ============= ============= Number of shares : Weighted average number of ordinary shares for the purpose of basic earnings per share 620,000,000 620,000,000 =========== =========== Diluted earnings per share is not presented as there were no dilutive potential ordinary shares in existence during the period. |